| Nurses ahead of vaccination’Seriously education’ Nurses in infectious diseases dedicated hospital nurses are receiving training for corona 19 vaccination nurses at the Gyeonggi Nursing Association in Paldal-gu, Suwon on the afternoon of the 17th. 2021.2.17 / Reporter Kim Do-woo [email protected] |
Ministry of Food and Drug Safety approves shipment for 787,000 people
Used over 18 years old… ‘Shinjung’ over 65
Pfizer’s product approval application’evaluation speed’
Celltrion to supply the treatment’Rekirona’
AstraZeneca’s COVID-19 vaccine has passed the national shipment approval process, the last stage of quality testing by health authorities. In addition, Celltrion has begun supplying the antibody treatment’Rekirona’ to medical institutions.
The Ministry of Food and Drug Safety announced on the 17th that it would approve 787,000 vaccines (1574,000 doses) of AstraZeneca for shipment. Vaccines must go through a national shipment approval procedure to check the quality before being distributed or marketed separately from the item license.
The Ministry of Food and Drug Safety quickly completed the approval for shipment to the country, which normally takes 2-3 months. The vaccine that received approval for shipment this time is the quantity manufactured by entrusting all processes by SK Bioscience. This vaccine will be used for the first domestic COVID-19 vaccine vaccination by the Korea Centers for Disease Control and Prevention.
The vaccine has been approved by the Food and Drug Administration to be used by all adults over the age of 18. However, there is a condition that the administration to the elderly 65 years or older must be carefully determined. Although there was no problem with safety, it was judged that there was no sufficient basis for judging the preventive effect for the elderly.
The Ministry of Food and Drug Safety is also speeding up the screening for approval of Pfizer’s COVID-19 vaccine. On the 25th of last month, Pfizer applied for a license for the vaccine to the Ministry of Food and Drug Safety. If it is as scheduled, it is expected to obtain permission after the first week of March.
On the other hand, Celltrion started supplying the Corona 19 antibody treatment drug’Rekirona’ (ingredient name Regdanvimab) to medical institutions on this day. I received an application for supply by medical institution the day before, and the supply will start in earnest on this day.
The treatment is provided free of charge to patients, and can be obtained by filling out a supply request form directly from 156 corona19 treatment medical institutions nationwide and applying to Celltrion Pharmaceutical.
Subjects to be administered are those who are 60 years of age or older among confirmed patients who do not require oxygen therapy and do not need oxygen therapy, or have underlying diseases such as cardiovascular disease, chronic respiratory disease, diabetes, hypertension, or patients with pneumonia.
/Kim Sung Joo [email protected]
–
